MA34727B1 - Imidazolylimidazoles condensés utilisés comme composés antiviraux - Google Patents

Imidazolylimidazoles condensés utilisés comme composés antiviraux

Info

Publication number
MA34727B1
MA34727B1 MA36000A MA36000A MA34727B1 MA 34727 B1 MA34727 B1 MA 34727B1 MA 36000 A MA36000 A MA 36000A MA 36000 A MA36000 A MA 36000A MA 34727 B1 MA34727 B1 MA 34727B1
Authority
MA
Morocco
Prior art keywords
antiviral compounds
compounds
imidazolylimidazoles
condensed
condensed imidazolylimidazoles
Prior art date
Application number
MA36000A
Other languages
English (en)
Inventor
Elizabeth M Bacon
Jeromy J Cottell
Ashley Anne Katana
Darryl Kato
Evan S Krygowski
John O Link
James Taylor
Chinh Viet Tran
Martin Teresa Alejandra Trejo
Zheng-Yu Yang
Sheila Zipfel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47324426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34727(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA34727B1 publication Critical patent/MA34727B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

L'invention a pour objets des composés antiviraux, des compositions pharmaceutiques contenant de tels composés, des méthodes thérapeutiques comprenant l'administration de tels composés et des procédés et des intermédiaires utiles à la préparation de tels composés.
MA36000A 2011-11-16 2013-06-10 Imidazolylimidazoles condensés utilisés comme composés antiviraux MA34727B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161560654P 2011-11-16 2011-11-16
PCT/US2012/065681 WO2013075029A1 (fr) 2011-11-16 2012-11-16 Imidazolylimidazoles condensés utilisés comme composés antiviraux

Publications (1)

Publication Number Publication Date
MA34727B1 true MA34727B1 (fr) 2013-12-03

Family

ID=47324426

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36000A MA34727B1 (fr) 2011-11-16 2013-06-10 Imidazolylimidazoles condensés utilisés comme composés antiviraux

Country Status (36)

Country Link
US (14) US20130164260A1 (fr)
EP (4) EP3431477B1 (fr)
JP (5) JP6082749B2 (fr)
KR (5) KR20190121406A (fr)
CN (2) CN105837584B (fr)
AP (1) AP2013006877A0 (fr)
AU (1) AU2012318253B8 (fr)
BR (1) BR112013012091A2 (fr)
CA (2) CA2815082C (fr)
CL (1) CL2013001428A1 (fr)
CO (1) CO6791562A2 (fr)
CR (1) CR20130231A (fr)
CY (2) CY1116987T1 (fr)
DK (2) DK2907816T3 (fr)
EA (4) EA023644B1 (fr)
EC (2) ECSP13012790A (fr)
ES (3) ES2544107T3 (fr)
HR (2) HRP20150725T1 (fr)
HU (2) HUE039966T2 (fr)
IL (5) IL226345A (fr)
LT (1) LT2907816T (fr)
MA (1) MA34727B1 (fr)
MD (2) MD4403C1 (fr)
ME (1) ME02196B (fr)
MX (4) MX377552B (fr)
MY (2) MY173045A (fr)
PE (2) PE20171444A1 (fr)
PH (2) PH12013500976A1 (fr)
PL (3) PL2907816T3 (fr)
PT (3) PT2635588E (fr)
RS (2) RS54207B1 (fr)
SG (1) SG10201700947UA (fr)
SI (3) SI2907816T1 (fr)
SM (2) SMT201800470T1 (fr)
UA (2) UA110354C2 (fr)
WO (1) WO2013075029A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883703B1 (ko) 2003-05-30 2009-02-12 파마셋 인코포레이티드 변형 불소화 뉴클레오시드 유사체
NZ619205A (en) 2009-05-13 2015-04-24 Gilead Pharmasset Llc Antiviral compounds
NZ726475A (en) 2010-11-17 2018-07-27 Gilead Pharmasset Llc Antiviral compounds
EP2730572B1 (fr) 2011-07-09 2015-09-16 Sunshine Lake Pharma Co., Ltd. Composés spiro en tant qu'inhibiteurs du virus de l'hépatite c
EP2709613B2 (fr) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Procédés permettant de traiter le virus de l'hépatite c (hcv)
UA110354C2 (uk) * 2011-11-16 2015-12-25 Гайлід Фармассет Елелсі Противірусні сполуки
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
UA118256C2 (uk) 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Комбінований склад двох противірусних сполук
WO2014122895A1 (fr) 2013-02-07 2014-08-14 保土谷化学工業株式会社 Composé ayant une structure cyclique de diazatriphénylène et élément électroluminescent organique
WO2014185995A1 (fr) * 2013-05-16 2014-11-20 Gilead Pharmasset Llc Traitements de l'hépatite c avec du sofosbuvir
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP6333372B2 (ja) * 2013-07-09 2018-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤の組み合わせ
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
EP3650014B1 (fr) * 2013-08-27 2021-10-06 Gilead Pharmasset LLC Formulation de combinaison de deux composés antiviraux
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN104418784B (zh) * 2013-09-04 2019-02-19 浙江九洲药业股份有限公司 一种抗病毒药物中间体的拆分方法
WO2015100144A1 (fr) 2013-12-23 2015-07-02 Gilead Sciences, Inc. Formes cristallines d'un composé antiviral
TW202014413A (zh) * 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
CN110372559A (zh) * 2014-12-29 2019-10-25 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
CN106008552B (zh) * 2015-03-01 2020-08-21 南京圣和药业股份有限公司 苯并[e]吡唑并[1,5-c][1,3]噁嗪类化合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017060820A1 (fr) * 2015-10-08 2017-04-13 Mylan Laboratories Limited Procédé de préparation de velpatasvir
CN105294713A (zh) * 2015-10-09 2016-02-03 重庆康施恩化工有限公司 Velpatasvir中间体及其制备方法
CN105801553B (zh) * 2016-04-12 2018-06-19 爱斯特（成都）生物制药股份有限公司 一种苯并色烯衍生物的制备方法
CN106916134B (zh) * 2016-04-14 2020-04-17 苏州楚凯药业有限公司 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
WO2017184670A2 (fr) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Méthodes de traitement d'infections à virus zika
EP3452038B1 (fr) * 2016-05-05 2022-07-06 Laurus Labs Limited Procédé de préparation d'intermédiaires utiles dans la préparation d'inhibiteurs du virus de l'hépatite c (vhc)
WO2017197046A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4491236A3 (fr) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
EP4483875A3 (fr) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
MX2018014377A (es) 2016-05-27 2019-03-14 Gilead Sciences Inc Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
WO2018006811A1 (fr) * 2016-07-08 2018-01-11 深圳市塔吉瑞生物医药有限公司 Composé d'imidazolyle substitué et composition pharmaceutique correspondante
KR101887969B1 (ko) * 2016-08-30 2018-08-13 한국과학기술연구원 항바이러스 활성을 가지는 카르바졸 화합물
CN107573355B (zh) * 2016-11-30 2020-03-17 上海博志研新药物技术有限公司 维帕他韦、其中间体及制备方法
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
WO2018237026A1 (fr) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. Dégrons et dégronimères à liaison n/o pour la dégradation de protéines
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
CN107655986B (zh) * 2017-09-08 2020-11-03 安徽一灵药业有限公司 一种维帕他韦有关物质的检测方法
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
CN108276421B (zh) * 2018-02-13 2019-08-06 浙江永太药业有限公司 一种维帕他韦的合成方法
EP4045040B1 (fr) 2019-10-18 2023-04-05 Wockhardt Limited Composés bicycliques contenant de l'azote
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
CN110981879B (zh) * 2019-12-09 2021-03-05 南通常佑药业科技有限公司 一种制备ns5a抑制剂-维帕他韦的方法
CN113072615B (zh) * 2021-03-24 2023-01-10 上海法默生物科技有限公司 一种维帕他韦中间体的制备方法
KR20240012476A (ko) 2021-05-21 2024-01-29 길리애드 사이언시즈, 인코포레이티드 지카 바이러스 저해제로서의 펜타사이클릭 유도체
CN117500494A (zh) 2021-06-17 2024-02-02 阿堤亚制药公司 有利的抗hcv联合疗法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
JP3347723B2 (ja) 1990-06-13 2002-11-20 グラツィエル，アーノルド 含リンプロドラッグ
ES2118069T3 (es) 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
AU2004235848B2 (en) 2003-05-09 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis C virus NS5B polymerase inhibitor binding pocket
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
CA2571984C (fr) 2004-07-16 2012-04-10 Gilead Sciences, Inc. Composes antiviraux
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2100606A4 (fr) 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd Préparation revêtue d'un film ayant une stabilité améliorée
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009102621A2 (fr) * 2008-02-11 2009-08-20 Qualcomm Mems Technologies, Inc. Procédés de mesure et de caractérisation de modulateurs interférométriques
AU2008350327B2 (en) 2008-02-12 2013-09-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2715839C (fr) 2008-02-13 2014-12-09 Bristol-Myers Squibb Company Imidazolyle diphenyle imidazoles inhibitrices du virus de l'hepatite c
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CA2750577A1 (fr) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c de type ns5a
WO2010096777A1 (fr) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibiteurs du ns5a du vhc
CA2753382C (fr) 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c
CA2756255A1 (fr) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Inhibiteurs bicycliques du vhc substitues
AU2010229795A1 (en) 2009-03-27 2011-10-13 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
AU2010249080A1 (en) 2009-05-12 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
NZ619205A (en) 2009-05-13 2015-04-24 Gilead Pharmasset Llc Antiviral compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ597982A (en) * 2009-09-04 2013-01-25 Glaxosmithkline Llc CHEMICAL COMPOUNDS for treating Hepatitis C virus
WO2011031904A1 (fr) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Inhibiteurs du virus de l'hépatite c
US20120276047A1 (en) * 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102791687B (zh) * 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
EP2516430B1 (fr) * 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales
BR112012022125A2 (pt) 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2809261A1 (fr) 2010-08-26 2012-03-01 Rfs Pharma, Llc Inhibiteurs puissants et selectifs du virus de l'hepatite c
WO2012048421A1 (fr) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Composés inhibiteurs de l'hépatite c
NZ726475A (en) 2010-11-17 2018-07-27 Gilead Pharmasset Llc Antiviral compounds
WO2012087976A2 (fr) 2010-12-21 2012-06-28 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
UA110354C2 (uk) 2011-11-16 2015-12-25 Гайлід Фармассет Елелсі Противірусні сполуки
WO2013101550A1 (fr) 2011-12-29 2013-07-04 Abbvie Inc. Compositions solides
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
EP3650014B1 (fr) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Formulation de combinaison de deux composés antiviraux
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置

Also Published As

Publication number Publication date
US10807990B2 (en) 2020-10-20
NZ610525A (en) 2017-05-26
PH12013500976A1 (en) 2016-10-26
MD4521C1 (ro) 2018-05-31
US8575135B2 (en) 2013-11-05
US20130177530A1 (en) 2013-07-11
MY173045A (en) 2019-12-20
ME02196B (fr) 2016-02-20
CY1116987T1 (el) 2017-04-05
US20140309432A1 (en) 2014-10-16
KR101890400B1 (ko) 2018-08-21
HUE039966T2 (hu) 2019-02-28
PH12015502839B1 (en) 2020-10-30
CA2815082A1 (fr) 2013-05-23
MX377552B (es) 2025-03-10
JP2021001230A (ja) 2021-01-07
HRP20150725T1 (hr) 2015-08-14
LT2907816T (lt) 2018-09-10
AU2012318253A8 (en) 2015-08-13
MD4403C1 (ro) 2016-09-30
KR102241651B1 (ko) 2021-04-20
CN105837584A (zh) 2016-08-10
CY1121225T1 (el) 2020-05-29
PT3431477T (pt) 2020-12-15
AP2013006877A0 (en) 2013-05-31
MX361735B (es) 2018-12-14
JP2015512860A (ja) 2015-04-30
HK1188989A1 (en) 2014-05-23
BR112013012091A2 (pt) 2019-09-10
JP6082749B2 (ja) 2017-02-15
KR20200117043A (ko) 2020-10-13
HRP20181384T1 (hr) 2018-12-28
HUE027733T2 (en) 2016-10-28
IL244123A0 (en) 2016-04-21
ECSP13012790A (es) 2013-10-31
EA201591244A1 (ru) 2016-02-29
EP3778606A2 (fr) 2021-02-17
EP2635588A1 (fr) 2013-09-11
US20150141326A1 (en) 2015-05-21
MD4521B1 (ro) 2017-10-31
IL252345B (en) 2022-01-01
SI2635588T1 (sl) 2015-10-30
CN103328480B (zh) 2016-05-25
AU2012318253B8 (en) 2015-08-13
EP2635588B1 (fr) 2015-06-10
KR20180095119A (ko) 2018-08-24
JP2016199593A (ja) 2016-12-01
US9051340B2 (en) 2015-06-09
EA202190619A1 (ru) 2021-09-30
ES2544107T3 (es) 2015-08-27
US20150299213A1 (en) 2015-10-22
US9809600B2 (en) 2017-11-07
IL226345A (en) 2016-03-31
US8921341B2 (en) 2014-12-30
IL244124A0 (en) 2016-04-21
EP3431477A1 (fr) 2019-01-23
KR102036469B1 (ko) 2019-10-24
MX2013005575A (es) 2013-09-05
MX346729B (es) 2017-03-30
SMT201800470T1 (it) 2018-11-09
DK2635588T3 (en) 2015-09-07
ES2687291T3 (es) 2018-10-24
US20180244683A1 (en) 2018-08-30
CR20130231A (es) 2013-09-19
WO2013075029A1 (fr) 2013-05-23
IL244122A0 (en) 2016-04-21
CN105837584B (zh) 2018-07-13
SMT201500197B (it) 2015-09-07
US20170145027A1 (en) 2017-05-25
SI3431477T1 (sl) 2021-01-29
IL226345A0 (en) 2013-07-31
RS57638B1 (sr) 2018-11-30
US20130156732A1 (en) 2013-06-20
US20140112885A1 (en) 2014-04-24
UA110354C2 (uk) 2015-12-25
US9868745B2 (en) 2018-01-16
NZ752834A (en) 2021-01-29
EA201890333A1 (ru) 2018-10-31
US20160083394A1 (en) 2016-03-24
ECSP18048718A (es) 2018-07-31
EA201390576A1 (ru) 2013-11-29
AU2012318253A1 (en) 2013-05-30
MD20150091A2 (ro) 2016-02-29
PL2907816T3 (pl) 2019-03-29
JP2018024705A (ja) 2018-02-15
EP2907816B1 (fr) 2018-06-13
AU2012318253B2 (en) 2015-08-06
DK2907816T3 (en) 2018-09-24
EA023644B1 (ru) 2016-06-30
US20130164260A1 (en) 2013-06-27
CL2013001428A1 (es) 2014-06-27
KR20190121406A (ko) 2019-10-25
EP3431477B1 (fr) 2020-10-14
KR20140096239A (ko) 2014-08-05
IL252345A0 (en) 2017-07-31
NZ720856A (en) 2017-12-22
EA030941B1 (ru) 2018-10-31
US20180186806A1 (en) 2018-07-05
JP2019206597A (ja) 2019-12-05
PT2635588E (pt) 2015-09-14
MD20130029A2 (en) 2013-09-30
PE20171444A1 (es) 2017-09-29
SG10201700947UA (en) 2017-03-30
MX2020010330A (es) 2020-10-22
MD4403B1 (ro) 2016-02-29
US20200071337A1 (en) 2020-03-05
US20210053981A1 (en) 2021-02-25
EP2907816A1 (fr) 2015-08-19
SI2907816T1 (sl) 2018-10-30
CA2884712A1 (fr) 2013-05-23
CN103328480A (zh) 2013-09-25
RS54207B1 (sr) 2015-12-31
US20190276468A1 (en) 2019-09-12
PL3431477T3 (pl) 2021-04-06
PT2907816T (pt) 2018-10-18
US9221833B2 (en) 2015-12-29
UA119437C2 (uk) 2019-06-25
PL2635588T3 (pl) 2015-10-30
US8940718B2 (en) 2015-01-27
CO6791562A2 (es) 2013-11-14
EA037883B1 (ru) 2021-05-31
CA2815082C (fr) 2015-07-07
PH12015502839A1 (en) 2019-05-15
MY201670A (en) 2024-03-12
ES2843023T3 (es) 2021-07-15
KR20210043734A (ko) 2021-04-21
EP3778606A3 (fr) 2021-03-03
NZ737924A (en) 2019-06-28
PE20141163A1 (es) 2014-09-21

Similar Documents

Publication Publication Date Title
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MD4496B1 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
MA34474B1 (fr) Agonistes de gpr40
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA38227B1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase
MX2012007410A (es) Compuestos antivirales novedosos.
MA38138A1 (fr) Dérivés inédits de quinolone
GB2511685A (en) Muscarinic m1 receptor agonists
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2019007696A1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA34308B1 (fr) Triazolopyridines substituées
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MA35941B1 (fr) Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale
MA33218B1 (fr) Applications therapeutiques de derives de quinazolinedione
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique